Drug Interactions between clarithromycin and Malarone Pediatric
This report displays the potential drug interactions for the following 2 drugs:
- clarithromycin
- Malarone Pediatric (atovaquone/proguanil)
Interactions between your drugs
No interactions were found between clarithromycin and Malarone Pediatric. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
clarithromycin
A total of 724 drugs are known to interact with clarithromycin.
- Clarithromycin is in the drug class macrolides.
-
Clarithromycin is used to treat the following conditions:
- Bacterial Endocarditis Prevention
- Bronchitis
- Dental Abscess
- Follicular Lymphoma (off-label)
- Helicobacter Pylori Infection
- Legionella Pneumonia
- Middle Ear Infections
- Mycobacterium avium-intracellulare, Prophylaxis
- Mycobacterium avium-intracellulare, Treatment
- Mycoplasma Pneumonia
- Nongonococcal Urethritis
- Pertussis
- Pertussis Prophylaxis
- Pharyngitis
- Pneumonia
- Sinusitis
- Skin and Structure Infection
- Skin or Soft Tissue Infection
- Strep Throat
- Tonsillitis/Pharyngitis
- Toxoplasmosis
- Upper Respiratory Tract Infection
Malarone Pediatric
A total of 125 drugs are known to interact with Malarone Pediatric.
- Malarone pediatric is in the drug class antimalarial combinations.
- Malarone pediatric is used to treat the following conditions:
Drug and food/lifestyle interactions
atovaquone food/lifestyle
Applies to: Malarone Pediatric (atovaquone / proguanil)
ADJUST DOSING INTERVAL: Food, particularly high-fat food, significantly enhances the oral absorption and bioavailability of atovaquone. In 16 healthy volunteers, administration of a single 750 mg dose of atovaquone suspension following a standard breakfast (23 g fat: 610 kCal) resulted in an approximately 3.4-fold increase in the mean peak plasma concentration (Cmax) and a 2.5-fold increase in the mean area under the plasma concentration-time curve (AUC) of atovaquone compared to administration following an overnight fast. In a study consisting of 19 HIV-infected volunteers receiving atovaquone suspension 500 mg/day, Cmax and AUC of atovaquone increased by 72% and 66%, respectively, in the fed state relative to the fasting state.
MANAGEMENT: To ensure maximal oral absorption, atovaquone products (suspension, tablet, or in combination with proguanil) should be administered with a meal or milky drink, or enteral nutrition at the same time(s) each day. Because plasma atovaquone concentrations have been shown to correlate with the likelihood of successful treatment and in some cases, survival, alternative therapies may be appropriate for patients who have difficulty taking atovaquone with food.
References (3)
- (2001) "Product Information. Mepron (atovaquone)." Glaxo Wellcome
- (2001) "Product Information. Malarone (atovaquone-proguanil)." Glaxo Wellcome
- Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT (2009) "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm, 66, p. 1438-67
clarithromycin food/lifestyle
Applies to: clarithromycin
Grapefruit juice may delay the gastrointestinal absorption of clarithromycin but does not appear to affect the overall extent of absorption or inhibit the metabolism of clarithromycin. The mechanism of interaction is unknown but may be related to competition for intestinal CYP450 3A4 and/or absorptive sites. In an open-label, randomized, crossover study consisting of 12 healthy subjects, coadministration with grapefruit juice increased the time to reach peak plasma concentration (Tmax) of both clarithromycin and 14-hydroxyclarithromycin (the active metabolite) by 80% and 104%, respectively, compared to water. Other pharmacokinetic parameters were not significantly altered. This interaction is unlikely to be of clinical significance.
References (1)
- Cheng KL, Nafziger AN, Peloquin CA, Amsden GW (1998) "Effect of grapefruit juice on clarithromycin pharmacokinetics." Antimicrob Agents Chemother, 42, p. 927-9
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.